Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study

Teketel Alemu Ersulo¹, Mengist Awoke Yizengaw²,³ and Behailu Terefe Tesfaye²,³*

Abstract

Background: Adverse drug events (ADEs) are an important public health problem with considerable clinical and economic costs. However, there are limited studies of ADE incidence in adult inpatients in low-income countries, particularly in Ethiopia. Hence, this study aimed to assess the incidence of adverse drug events and associated factors in patients hospitalized in the medical wards of Wolaita Sodo University teaching referral hospital (WSUTRH).

Methods: A prospective observational study was conducted involving 240 patients admitted to the medical wards of WSUTRH. A checklist was used for data collection, while standard tools were employed for assessing the probability and characterization of ADEs. A multifaceted approach involving daily chart review, patient interview, attendance at ward rounds and/or meetings, and staff reports were employed to collect the data. To identify factors independently associated with ADEs, logistic regression analysis was conducted using Stata version 15.

Results: Patients were followed from ward admission to discharge, accounting for 2200 patient-days of hospital stay. Overall, 976 medications were ordered during the hospital stay. Sixty-four ADEs were identified with an incidence of approximately 27 per 100 admissions and 29 per 1000 patient days. Of the total ADEs, 59% were preventable. Regarding the severity, 2% of the ADEs were severe, while 54% were moderate. The risk of ADEs increased with longer hospital stay (LOHS) \( p = 0.021 \), in patients with blood and immune disease diagnosis \( p = 0.001 \), use of cardiovascular medicines \( p = 0.028 \), and an increase in the number of medications prescribed \( p = 0.021 \).

Conclusions: In this study, ADEs were identified in about one-quarter of the participants. Longer hospital stays, blood and immune diseases, cardiovascular medicines use, and multiple medication use had increased the likelihood of ADE occurrences. The majority of the ADEs were preventable, indicating the existence of a window of opportunity to ensure patient safety.

Keywords: Adults, Medication, Undesirable events, Predictors

Introduction

The evolution of clinical therapeutics has positively affected public health, but these benefits have also been accompanied by increased risks of medical harm [1, 2]. Adverse drug event (ADE) is the most common cause of medical harm. It is defined as an injury resulting from the use of medication [3], which can be preventable or
non-preventable [4]. It is estimated that about half of ADE incidences are preventable [2, 5–8].

There are various strategies to detect ADEs in hospital settings. The most common methods involve spontaneous reporting systems, patient interviews and chart reviews, trigger tools, and computerized monitoring systems [9, 10]. The traditional, spontaneous reporting system is presumed ineffective because of factors such as under-reporting and lack of essential data for identification of the causality of suspected drugs [10]. There is no single standard method to employ, thus the use of multiple strategies to maximize the detection of ADE incidence is recommended [11].

Globally, ADEs are among the major public health concerns with variable incidence reports across the studies. For instance, a study from Japan reported 29.2% [12], a study from Saudi-Arabia revealed 8.5% [13], in Africa, studies from Uganda recorded 25% [14], while a study from Ethiopia reported 36.4% [15] ADE incidences. These variable reports are attributed to factors such as differences in the strategies employed for detecting ADEs [9, 10], the specific study definition of ADEs, and others. Adverse drug events often lead to hospital admission [16–25], prolongation of hospital stay [5, 6, 26–29] and mortality [26], increasing the healthcare expenditures [20, 26, 30–32]. Healthcare professionals are also indirectly affected by the ADEs because of the loss of public’ confidence in the health service [33]. Thus, provided that more than half of ADE incidences are preventable [2, 5–8], it is highly imperative to identify ADE risk factors and prevent their incidences. Various studies had reported sex, age, length of hospital stay, comorbidity, specific drug class, medication error, and the number of medications as the major risk factors for ADE incidences [6, 14, 34–37].

There are limited studies on ADEs in the Ethiopian hospital settings. In a cross-sectional study on adverse drug reaction-related hospitalization from Jimma University medical centre, adverse drug reactions accounted for 10.3% of hospital admissions [38]. Another study from the same setting found that above quarter of patients (26.6%) admitted to the hospital experienced ADEs during their hospital stay [15]. Because of the scarce availability of such studies in Ethiopia, this study was proposed and conducted to assess the incidences and determinants of ADE among patients hospitalized in the medical wards.

Material and methods
Study area and period
The study was conducted from February 2021 to July 2021, in the medical wards of WSUTRH, in Sodo town, Southwest Ethiopia. Sodo town is 330km away from the national capital, Addis Ababa. The hospital has 1019 staff; 418 professionals, and 601 support staff. The hospital provides health services for about 12,944 inpatients and 109,091 outpatients per year. There are two medical units under the medical ward, i.e., the male and the female ward. The medical ward had 3 internists, 3 general practitioners, 10 nurses, and 2 clinical pharmacists. It has 3 rooms and 49 beds for both male and female adult inpatient services.

Study design
A prospective observational study design was employed.

Source and study population
Source population
All adult inpatients from the medical wards of WSUTRH.

Study population
All adult patients admitted to the medical wards of WSUTRH during the data collection period who fulfilled the inclusion criteria.

Eligibility criteria
All patients aged ≥18 years old were included in the study, while patients who declined to take part in the study, with hospital stay < 24 hrs, and who lost follow up were excluded.

Sample size and sampling procedure
Sample size (n) was calculated using a single population proportion formula considering the proportion of ADE occurrence (P) of 0.36 [15]; level of confidence (Z = 1.96) of 95%; the size of patients admitted in the previous 6 months before this study (N) = 640; and margin of error (W) of 5%. The final sample size was 240.

Study variables
Incidence of ADE was a dependent variable, while the independent variables were: sociodemographic and behavioural variables [Age, sex, residence, marital status, educational status, occupation, alcohol use, cigarette smoke, and traditional medicine use history], clinical and related factors [history of hospitalization in the previous 3 months, past medical history, current diagnosis, Charlson’s comorbidity index score, and LOHS], medications and related factors [past medication history, ADE history, number of medications, and class of medication used].

Data collection tools, procedures, and case detection
The data collection checklist employed in the present study was developed after reviewing relevant literature. The checklist comprises sociodemographic, behavioural, medication, and clinical-related variables. Initially, the
A tool was designed to collect data from patients and attendants, like socio-demographic, informed consent, and patient information sheet) were translated to two locally dominant languages (Wolaitigna and Amharic) and back to English.

Two clinical pharmacists were employed as data collectors, while one internal medicine resident was employed as a supervisor. The data collectors enrolled and interviewed eligible participants and reviewed medical charts daily for all admissions. They strictly followed changes in medication experiences and abnormal laboratory values to identify incidences of ADEs. The medical ward staff and patients were briefed on the objectives of the study and requested cooperation to report in case of any event occurrence (self-report). Besides this, a standard trigger tool [39], which involves links to potential ADEs because either they are antidotes or given to reverse the action of a drug responsible for ADE, was used to increase the ADEs detection rate. The responsible physician was contacted in case of medication management changes to clarify the changes made. Also, the clinical pharmacists attended clinical rounds and visited wards daily to solicit any alerts for ADE. Patients were interviewed using a questionnaire that contains sociodemographic and behaviour variables, medical and medication history. The clinical pharmacist forwarded any suspected ADE cases for further evaluation to a multidisciplinary team composed of physicians (internists, general practitioners), ward pharmacists, and clinical nurses. When ADE was detected, the data collectors recorded the event in the ADE documentation format.

**Methods for classifying diagnosis, medications prescribed, and medication-related events**

In the present study, diagnosed diseases are classified according to the international classification of diseases, tenth edition (ICD-10) [39], and scored using the Charlson comorbidity index (CCI) score [40]. The prescribed medications are categorized in line with anatomical, therapeutic, and chemical classification. During patient follow-up in the ward, in case of suspicion on the medication safety events, they were further evaluated and classified.

**Adverse drug event case evaluation**

In this study, the term ADE is contextualized as an injury resulting from the use of medication at doses used for prophylaxis, diagnosis or therapy [41]. We employed standard tools to assess the causality, categorize the severity and determine the preventability of the ADEs. The causality of all suspected ADEs was assessed using the modified Naranjo Causality Scale (MONARCS) [42]. This validated tool scores the likelihood that an event is drug-related. The algorithm comprises questions that evaluate factors like the temporal association of drug administration and ADE occurrence, response to de-challenge or re-challenge, alternative explanations for the event, any objective evidence, and previous drug exposure. They are answered as either yes, no, or do not know. Different point values (−1, 0, +1 or +2) were assigned to each answer that yields the following associations between total score and causal relationship: [1] 1 through 4 points equals possible [2]; 5 through 8 points equals probable; and [3] 9 or more points equals definite.

The severity of the ADEs was categorized based on the modified Hartwig Severity Assessment Scale [43]. Based on this scale, the severity of ADEs was classified as mild (level 1 and 2), moderate (level 3 and 4), or severe (level 6), depending on factors like requirements for change in medication, increase in in-hospital stay and led to permanent injury. The Preventability of the ADEs was determined using the explicit criteria developed by Schumock and Thornton [42]. The tool has three sections, namely definitely preventable, probably preventable, and non-preventable. Section A comprises five questions, while section B has four questions. All the answers were categorized as yes or no. Adverse drug events were definitely preventable if the answer is yes to one or more questions in section A. If the answers were all negative, the assessors will proceed to section B. Adverse drug event is probably preventable if the answer is yes to one or more questions in section B. If answers were all negative, section C proceeded. In Section C, the ADEs were non-preventable. The categorization of events (causality, severity, and preventability) was further strengthened by involving responsible clinicians. The reviewers reached a consensus through discussion in case of discordant classification.

**Data processing and analysis**

Epi-Data version 4.6.0.2 and Stata version 15 were employed for data entry and analysis, respectively. Frequency and percentages were used to present categorical variables, whereas continuous variables were described using mean ± Standard deviation (SD). Outcomes were reported in terms of the institute for health care improvement (IHI) ADE reporting metrics: ADE incidence per 100 admissions, per 1000 person-days [39], per 100 medications ordered, and proportions. The incidence of ADEs per 100 admissions and 100 medications ordered was calculated by dividing the total number of ADEs identified by the total number of admissions and a total number of medications ordered respectively and multiplied by 100. Similarly, the incidence of ADEs per 1000 person-days was calculated as the total number of ADEs identified divided by the total number of patient days multiplied by 1000.
Before running regression analysis, cell adequacy was checked for each categorical variable. Variables were tested for multicollinearity by collinearity diagnostics. Then, bivariate logistic regression analysis was carried out to recruit candidate variables for multivariate logistic regression analysis. Thus, variables with a p-value < 0.25 were inserted into a multivariate logistic regression to identify statistically significant predictors of ADE occurrence. Crude and adjusted Odds ratio, including p-value and 95% confidence interval, was reported. A p-value < 0.05 was considered statistically significant.

Quality assurance
To ensure the quality of the data, data collectors were trained on the objectives of the study, the data collection checklist, and how to assess and record ADEs before starting the work. During the actual data collection, they were evaluated & supported when demand ensues, especially on how and which data to collect from the patient chart. Supervision and daily checkup of filled data collection forms were done. The ward staff were informed of the aim of the study to facilitate the report habit of ADE incidences. Additionally, frequent consultations of the medical ward staff was done to stimulate further medication safety event/incident report verbally or to use the designed reporting format to maximize data yield. The quality of the data was assured by doing a pretest on 5% of the actual sample size before the actual data collection to check the consistency and validity of the data collection format.

Results
Overview
Overall, 295 patients were approached during the study period. Of these, 55 patients were rationally excluded and 240 patients were included in the study (Fig. 1).

Socio-demographic and behavioural characteristics of the participants
The overall mean age of participants in this study was 44 (±18) years. Most participants (52.5%) were female. Regarding residence, both rural and urban residents accounted for an equal proportion (50%). Relatively, most participants in this study attended primary school (40.8%) and merchants (27.5%) (Table 1).

Clinical and related factors of the study participants
Above two-thirds of the participants (67.5%) had a past hospitalization history. According to the ICD-10 disease category, diseases of the digestive system (19.2%), infectious and parasitic diseases (17.5%), and diseases of the respiratory system (14.6%) were the three most common diseases recorded. After admission to the wards, diseases of the circulatory system (42.1%), diseases of

Table 1  Sociodemographic and behavioural characteristics of study participants at WSUTRH, February 2021 to July 2021

| Variable               | Frequency | %   |
|------------------------|-----------|-----|
| Sex                    |           |     |
| Male                   | 114       | 47.5|
| Female                 | 126       | 52.5|
| Age, year (±18)        |           |     |
| Male                   | 44 (±18)  |     |
| Female                 |           |     |
| Residence              |           |     |
| Urban                  | 120       | 50.0|
| Rural                  | 120       | 50.0|
| Marital status         |           |     |
| Married                | 191       | 79.6|
| Single                 | 47        | 19.6|
| Divorced               | 2         | 0.83|
| Educational status     |           |     |
| No formal education    | 51        | 21.2|
| Primary                | 98        | 40.8|
| Secondary              | 78        | 32.5|
| Tertiary               | 13        | 5.4 |
| Occupation             |           |     |
| Student                | 41        | 17.1|
| Gov’t employee         | 58        | 24.2|
| Merchant               | 66        | 27.5|
| Self-employed          | 15        | 6.2 |
| Farmer                 | 26        | 10.8|
| Unemployed             | 24        | 10.0|
| NGO                    | 7         | 2.9 |
| Retired                | 3         | 1.2 |
| Alcohol use history    | 7         | 2.9 |
| Cigarette smoke history| 7         | 2.9 |
| Traditional medicine use history | 8 | 3.3 |

NGO Non-Governmental Organization
the respiratory system (38.3%), diseases of the blood and immune mechanism (30%), and diseases of the digestive system (30%) were the most common. The mean Charlson's comorbidity index score was 2.0 (±2.13). The participants' average length of hospital stay (LOHS) was 9 (±6.6) days, and about 2.1% of the patients had a clinical outcome of death (Table 2).

**Medications and related factors of study participants**

Of the included patients, 46.7% of them had a history of medication use during the 3 months before the study period. Of them, most patients were taking antibiotics (25%), gastrointestinal medicines (14.2%), cardiovascular medicines (12.9%), and antimalarial (12.5%). During admission, above one quarter (27%) of the patients were taking medication. During the entire hospital stay (current medications), 976 medications have been ordered and, on average, each patient has been prescribed 4 (±1.9) medications. Of these, antibiotics (65%) were the leading class, followed by gastrointestinal medicines (33.3%) (Table 3).

**Adverse drug events and related factors**

**Incidence of ADEs**

The study participants accounted for 2200 patient days, and 64 ADEs were identified in 58 (24.2%) patients. The incidence of ADEs was approximately 27 (95% CI, 21.03–32.30) per 100 admissions, 29 per 1000 patient days, and 6 per 100 medication orders.

**Causality, severity, and preventability of ADEs**

Using the Naranjo causality assessment algorithm for ADE, 15.5% of ADEs were definite, 68.9% ADEs were probable, and 15.5% of ADEs were possible. According to the modified Hartwig ADE severity assessment scale, 43.7% ADEs were mild, 54.7% ADEs were moderate, and 1.6% ADEs were severe (Table 4).

Assessing ADEs preventability using the modified Schumock and Thornton preventability criteria, 28.1% ADEs were definitely preventable, 31.3% ADEs were probably preventable, and 40.6% of the ADEs were non-preventable.

---

**Table 2** Clinical and related factors of the study participants at WSUTRH, February 2021 to July 2021

| Variables                                      | Frequency | %   |
|------------------------------------------------|-----------|-----|
| History of hospitalization in the previous 3 months | 162       | 67.5|
| Past medical history based on ICD-10 code        |           |     |
| K00-K95                                        | Diseases of the digestive system | 46  | 19.2|
| A00-B99                                        | Infectious and parasitic diseases | 42  | 17.5|
| J00-J99                                        | Diseases of the respiratory system | 35  | 14.6|
| I00-I99                                        | Diseases of the circulatory system | 33  | 13.7|
| E00-E99                                        | Endocrine, nutritional, and metabolic diseases | 3   | 1.2|
| G00-G99                                        | Diseases of the nervous system | 3   | 1.2|
| C00-D49                                        | Neoplasms | 2   | 0.8|
| Current diagnosis based on ICD-10 code          |           |     |
| I00-I99                                        | Diseases of the circulatory system | 101 | 42.1|
| J00-J99                                        | Diseases of the respiratory system | 92  | 38.3|
| D50-D89                                        | Diseases of the blood and immune mechanism | 72  | 30.0|
| K00-K95                                        | Diseases of the digestive system | 72  | 30.0|
| A00-B99                                        | Infectious and parasitic diseases | 61  | 25.4|
| N00-N99                                        | Diseases of the genitourinary system | 45  | 18.7|
| E00-E99                                        | Endocrine, nutritional, and metabolic diseases | 27  | 11.2|
| G00-G99                                        | Diseases of the nervous system | 22  | 9.2|
| L00-L99                                        | Diseases of the skin and subcutaneous tissue | 6   | 2.5|
| C00-D49                                        | Neoplasms | 5   | 2.1|
| CCI score                                      | 2.0±2.1                                          |
| LOHS                                           | 9±6.6                                             |
| Number of deaths                               | 5                                                  |

CCI Charlson comorbidity index, ICD-10 International Classification of Diseases 10th version, LOHS Length of hospital stay, SD Standard deviation, WSUTRH Wolaita Sodo University teaching referral hospital
System organ class affected by ADEs

The Gastrointestinal (27%) and central nervous (23%) systems were the most frequently affected organ systems by the ADEs, followed by the endocrine and metabolic cardiovascular systems (each 10.9%) (Table 5).

Medications and related factors

In terms of class, most ADEs were caused by cardiovascular medicines, diuretics, antiepileptics, antibiotics, and anti-anaemic agents. Diuretics, cardiovascular, antiepileptic, and antibiotic medicines accounted for about 50% of ADEs (Fig. 2).

Factors associated with the occurrence of ADEs

In the bivariate logistic regression analysis, nineteen variables had a p-value < 0.25 and were recruited for multivariate logistic regression. Finally, four variables were independently associated with ADE incidence. Blood and immune disease diagnosis (AOR = 3.925, 95% CI: 1.709–9.013, p = 0.001), LOHS (AOR = 1.066, 95% CI: 1.009–1.125, p = 0.021), cardiovascular medicine prescription during the study period (AOR = 3.368, 95% CI: 1.137–9.979, p = 0.028), and the number of medications prescribed (AOR = 1.310, 95% CI: 1.041–1.647, p = 0.021) increased the risk of ADE incidences (Table 6).

Discussion

During the study period, patients, prescription orders, and laboratory results were meticulously monitored to pick up any incidences of ADEs. Overall, 64 ADEs were noted in 58 patients with an incidence rate of about 27 (95% CI, 21.03–32.30) per 100 admissions. This implies that ADEs pose a real burden on medical patients. Comparable incidences had been reported in multiple studies. Using a similar method, in a study by Takeshi M from Japan, 29.2 (95% CI, 27.7–30.7) incidence of ADEs were noted per 100 admissions [12]. Another prospective study by Ronald K involving Ugandan hospitalized patients confirms that the incidence rate of possible ADEs was 25 (95% CI, 22–29) per 100 admissions [14]. However, a study from Saudi Arabia reported that the incidence of ADEs was 8.5 (95% CI, 6.8–10.4) per 100 admissions [13]. This discrepancy might be explained by a variation in methods employed to detect ADEs. A study from Saudi Arabia relied mainly on information recorded in the medical records and heightened awareness by nurses only. Thus, some ADE incidences that were not documented in the medical record or otherwise reported might likely be missed.

In the present study, the relationship between the drug and events, as measured by the Naranjo algorithm showed 15.5% definite, 68.9% probable, and 15.5% possible, which is comparable with a prospective study from Morocco and the United Kingdom (UK) where most of the events (67 and 66.5%, respectively) had probably related to the suspected medications [5, 6]. Using the same algorithm for causality assessment, a prospective study from India also identified about 71.9% ADEs were probable, and 26.1% were possible [44]. However, a cross-sectional study in Sweden reported fewer results of definite (1%) and probable (29%) ADEs [45]. These fewer

| Variables                        | Frequency | %   |
|----------------------------------|-----------|-----|
| History of medication in the past 3 months | 112       | 46.7|
| Taking medications during admission | 65        | 27.1|
| Had history of adverse drug event(s) | 11        | 4.6 |

| Past medication history          |            |     |
|----------------------------------|------------|-----|
| Antibiotics                      | 60         | 25  |
| Gastrointestinal medicines       | 34         | 14.2|
| Cardiovascular medicines         | 31         | 12.9|
| Antimalarials                    | 30         | 12.5|
| Analgesics                       | 8          | 3.3 |
| Antituberculosis                 | 7          | 2.9 |
| Antiasthmatic                    | 6          | 2.5 |
| Antianaemic agents               | 6          | 2.5 |
| Antiepileptic drugs              | 3          | 1.2 |
| Antipsychotic                    | 3          | 1.2 |
| Antithyroid agents               | 3          | 1.2 |
| Anticoagulants                   | 2          | 0.8 |

| Current medications             |            |     |
|----------------------------------|------------|-----|
| Antibiotics                      | 156        | 65  |
| Gastrointestinal medicines       | 80         | 33.3|
| Antimalarials                    | 53         | 22.1|
| Vitamins and anti-anaemic agents | 44         | 18.3|
| Cardiovascular medicines         | 23         | 9.6 |
| Antidiabetic agents              | 20         | 8.3 |
| Steroids                         | 16         | 6.7 |
| Anticoagulants                   | 14         | 5.8 |
| Antiepileptic drugs              | 14         | 5.8 |
| Analgesics                       | 10         | 4.2 |
| Antipsychotic agents             | 7          | 2.9 |
| Antiplatelets                    | 6          | 2.5 |
| Anti-dyslipidemia agents         | 8          | 3.3 |
| Antituberculosis agents          | 5          | 2.1 |
| Anti-asthma agents               | 3          | 1.2 |
| Antiviral agents                 | 2          | 0.8 |
| Number of medications            | 4.1 ± 1.9  |    |
results might be because of the variation in study design. A study from Sweden is a retrospective study, and thus missing some points which need subjective evaluation to know causality might happen.

In the study of ADEs, a key aspect is the possibility of prevention. In our study, more than half (59%) of ADEs identified were preventable. This implies that ensuring safe medication therapy is possible in the majority of patients admitted to medical wards. This finding is nearly similar to results from studies performed in Italy (69.4%) [6] and the United States (72%) [7]. Similarly, other prospective studies in the UK and Rabat showed that over half of the ADEs, 54 and 65%, respectively, were deemed possibly or definitely avoidable [5, 8]. However, the data from a multicenter observational study carried out in Netherland [36] showed lower preventability for ADEs (15.4%) compared to our study findings. This could be explained by the differences in the unit, as differences in the drugs used in the surgical inpatient setting could have contributed to these differences, and it might also be from differences in the health care systems.

According to the modified Hartwig ADEs Severity Assessment Scale, our study shows that most of the ADEs were mild (43.7%) or moderate (54.7%) in severity. This is in line with several other studies of hospital inpatients. A Prospective study by Davies E from the UK showed that approximately three-quarters of ADRs were scored at level 3 or below on the Hartwig scale [5]. Similarly, a study conducted in Ethiopia also agrees with our result, in which, 52.6% were moderate, and 37.1% were mild [15]. Contrary to the present study, in a multicenter, retrospective cohort study from Massachusetts, United States of America, about half of ADEs were rated as severe (serious in 49.4% and life-threatening in 11.7%) [46]. This inconsistency in severity might be due to the difference in the ward settings considered; all admission services were included except for the psychiatric and neonatal services in the later study. The higher mean age (52.5 years) of the patients in the later study could also relate to differences in results. Older patients take more medications and are more vulnerable to specific medication adverse effects than younger patients.

The most frequent system organs influenced by ADEs in our study were in line with other recent studies. In the present study, the gastrointestinal (27%) and central nervous systems (23%); followed by the endocrine and metabolic (11%), and cardiovascular systems (11%) were among the most frequently affected organ systems. This result is consistent with reports of a study conducted in four tertiary care public sector hospitals in Pakistan, in which the gastrointestinal tract accounted for one-third (33.3%) of organ systems affected by ADEs [47]. Similarly, a study from India showed that the gastrointestinal tract (51.7%) is the most commonly involved system [48]. Also in agreement with the current study, gastrointestinal (46%) and neurological (23%) disorders were the commonest system organ classes affected in Uganda [14]. Another prospective study in Rabat showed that metabolic disorders and cardiovascular (20.8% each) are system organ classes affected by ADEs [8].

Multivariate analysis showed that LOHS, use of cardiovascular medicines, diseases of the blood and immune, and the number of medications predicted the occurrence

| **Level** | **Description** | **Frequency** | **%** |
|---------|-----------------|---------------|-------|
| 1       | An ADE occurred but required no change in treatment with the suspected drug | 15 | 23.4 |
| 2       | The ADE required that treatment with the suspected drug be held, discontinued, or otherwise changed. No antidote or other treatment requirement was required. No increase in hospital stays. | 13 | 20.3 |
| 3       | The ADE required that treatment with the suspected drug be held, discontinued, or otherwise changed AND/OR an antidote or another treatment was required. No increase in hospital stays. | 23 | 35.9 |
| 4       | Any Level 3 ADE which increases the length of stay by at least 1 day. | 12 | 18.7 |
| 5       | Any level 4 ADE which requires intensive medical care. | 0 | 0 |
| 6       | The ADE caused permanent harm to the patient | 1 | 1.6 |
| 7       | The ADE which led to the death of the patient | 0 | 0 |
| Total   | | 64 | 100 |

* 1&2 = mild, 3&4 = moderate, 5–7 = severe

ADES Adverse drug events, WSUTRH Wolaita Sodo University teaching referral hospital
of ADEs in this study. As LOHS increases, the risk of occurrence of ADEs increased by 1.07 times ($p = 0.019$). Similarly, in a prospective cohort study from Japan, a significantly high length of hospitalizations ($p < 0.01$) was reported in patients who experienced ADE than in those who did not, with shorter stays for the latter group [49]. A Prospective analysis from the UK reported that the median length of stay for patient episodes that resulted in an ADE was 20 days, compared to 8 days ($p < 0.0001$) for those episodes without ADEs [5]. Prospective observational studies in children and adults in Ethiopia revealed that patients with a prolonged length of stay were more associated with the occurrence of ADEs [15, 50]. This could be explained as patients with longer LOHS suffer from more severe conditions, multiple comorbid diseases, and had a higher dose of different drugs.

In our study, patients who use cardiovascular medicines were about four times more likely to experience ADEs ($p = 0.014$) than those without these medications. This is in line with a similar study conducted in the USA [46]. Other studies by Claudio B., and Rozenfeld S., also stated that cardiac therapy (9.6 and 28% respectively) is a therapeutic group that is frequently associated with

### Table 5: Classification of incident ADEs by organ system, WSUTRH, February 2021 to July 2021

| Organ system                  | Incidence | Adverse drug events | Medications                                      |
|-------------------------------|-----------|---------------------|--------------------------------------------------|
| Gastrointestinal              | 17 (26.7) | Dyspepsia 3 (4.7)   | Diclofenac (2), atorvastatin (1)                 |
|                               |           | Upper GI bleeding 2 (3.1) | Aspirin (1), diclofenac (1)                     |
|                               |           | Diarrhoea 3 (4.7)    | Clarithromycin (1), Omeprazole (2)              |
|                               |           | Vomiting 5 (7.8)     | Digoxin (1), iron sulfate (4)                   |
|                               |           | Loss of appetite 2 (3.1) | Aspirin (1), atorvastatin (1)                  |
|                               |           | Constipation 2 (3.1)  | Haloperidone (1), tramadol (1)                  |
| Central nervous system        | 15 (23.4) | Loss of consciousness 1 (1.6) | Furosemide (1)                                   |
|                               |           | Sedation 2 (3.1)     | Diazepam (2)                                     |
|                               |           | Dizziness 2 (3.1)    | Furosemide (2)                                   |
|                               |           | Seizure 3 (4.7)      | Insulin (1), tramadol (2)                        |
|                               |           | Hallucination 3 (4.7) | Phenytoin (1), Phenobarbitone (2)               |
|                               |           | Headache 4 (6.2)     | Nifedipine (2), enalapril (2)                   |
| Endocrine and metabolic       | 7 (10.9)  | Hypokalemia 1 (1.6)  | Spirolactone (1)                                 |
|                               |           | Hyperglycemia 1 (1.6) | Dexamethasone (1)                                |
|                               |           | Hypocalcemia 2 (3.1)  | Phenytoin (1) furosemide (1)                    |
|                               |           | Hypokalemia 2 (3.1)  | Furosemide (1)                                   |
|                               |           | Hypoglycemia 1 (1.6)  | Insulin (1)                                      |
| Cardiovascular system         | 7 (10.9)  | Hypotension 2 (3.1)  | Furosemide (2)                                   |
|                               |           | Peripheral oedema 1 (1.6) | Nifedipine (1)                                   |
|                               |           | Bradycardia 3 (4.7)  | Propranolol (2), digoxin (1)                    |
|                               |           | Shock 1 (1.6)        | Propranolol (1)                                  |
| Neuromuscular and skeletal    | 5 (7.8)   | Muscle stiffness 3 (4.7) | Chlorpromazine (3)                              |
|                               |           | myalgia 2 (3.1)      | Atorvastatin (2)                                 |
| Dermatologic                  | 5 (7.8)   | Skin rash 3 (4.7)    | amoxicillin/clavulanate (Augmentin) (1), cotrimoxazole (2) |
| Respiratory                   | 4 (6.2)   | Injection site phlebitis 2 (3.1) | Erythromycin (1), vancomycin (1)              |
|                               |           | Cough 2 (3.1)        | Enalapril (2)                                    |
| Immune system                 | 2 (3.1)   | Loss of hearing 1 (1.6) | Gentamycin (1)                                  |
| Immune system                 | 2 (3.1)   | respiratory depression 1 (1.6) | Phenobarbitone (1)                             |
| Hematologic                   | 2 (3.1)   | Allergy 2 (3.1)      | Ibuprofen (1), aspirin (1)                       |
|                               |           | Nose bleeding 1 (1.6) | Enoxaparin (1)                                  |
|                               |           | Anemia 1 (1.6)       | Artesunate (1)                                  |
| Total                         | 64 (100)  |                     |                                                   |

ADE Adverse drug event
ADEs [6, 15]. Thus, cautious prescription and frequent review of this class of medication is imperative.

The present study revealed that disease of the blood and immune is one of the significant predictors of ADE incidences. In agreement with this, a study conducted in Lima Peru found that anaemia, which is in the blood and immune diseases category, was independently associated with ADEs incidence ($p = 0.001$) [51]. Another study from Ethiopia by Merid also showed that patients who had anaemia were three times more likely to experience ADEs than patients who had no anaemia [52]. The more the medications that are prescribed, the more possibility of ADE incidences [53]. Likewise, in our study, the more medications that are prescribed for a patient, the greater the risk of ADEs ($p = 0.027$). Comparable to this, a prospective study by Nguyen T., in France confirms ADEs are significantly associated with the number of prescribed drugs ($P < 0.001$) [54]. Also, in a study from Brazil, the use of ten or more medications was associated with the occurrence of ADEs ($p$-value < 0.01) [55]. Our finding was also in agreement with studies conducted in Saudi Arabia and Uganda [14, 56]. Similarly, a study in the UK showed that the number of medicines taken was significantly higher than in those episodes not associated with an ADR ($p < 0.001$) [5]. This is because the prescribing of multiple drugs increases the risk of drug-drug interactions and the additive effects of multiple medications.

**Strength and limitations of the study**

The strength of this study involves: 1) the prospective follow-up of the admitted patients allowed a more reliable recording of both the medication history and symptoms and the assessment of causality and using of standard scales given. It has helped to capture those ADE incidences which might have been missed with retrospective chart review study designs. 2) This study has employed a standard trigger tool besides the traditional way of identifying ADEs using self-report only. This increases the probability of detecting ADEs. This study is not without limitations. 1) Though statistically acceptable, the sample size in the present study is small, which could have decreased the power of the study. 2) The inclusion of a single academic hospital could also limit the generalizability of the study results. 3) To be certain of the ADEs causality, besides other scores, detection of some laboratory specimen concentrations of the medicine should be applied. But this is not done in our setting, which may affect the causality score. 4) Unfortunately, we employed Schumock and Thornton criteria on the bedside for spot ADE preventability assessment only and didn’t collect specific elements fulfilled under each of the three sections, namely definitely preventable, probably preventable, and non-preventable on the data collection tool during the study period. 5) There might be recall bias, especially in those patients who do not have a patient card.
Conclusion
This study revealed ADEs incidences in about one-quarter of the participants. Longer hospital stays, blood and immune diseases, cardiovascular medicines, and multiple medication use had increased the likelihood of ADE occurrences. More than half (59%) of the ADEs were preventable. Based on findings, targeting hospitalized patients with an extended length of hospital stay, receiving cardiovascular medicines, multiple medication users, and proactive disease prevention, especially blood and immune diseases could help wean ADE incidences. Furthermore, the authors recommend a prospective and multicenter study addressing the limitations listed in this study.

Abbreviations
ADEs: Adverse Drug Events; AOR: Adjusted odds ratio; CCI: Charlson’s comorbidity index; COR: Crude odds ratio; ICD: International Classification of Diseases; LOHS: Length of hospital stay; MONARCS: Modified Naranjo causality scale; SD: Standard deviation; WSUTRH: Wolaita Sodo university teaching referral hospital.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40360-022-00570-w.

Acknowledgements

We acknowledge Jimma University’s research and innovation office for funding this project. Our gratitude also goes to the administration staff and clinicians working in the medical wards of WSUTRH for their kind cooperation.

Authors’ contributions

T.A.E., B.T.T. and M.A.Y. conceptualized and designed the study, performed the analysis and interpretation of data, B.T.T. drafted the manuscript and T.A.E., and M.A.Y. critically reviewed it. All authors read and approved the final manuscript.

Authors’ information

TAE: Clinical pharmacist, logistic officer in Hadiya Zone, West Badewacho Woreda Health Office, Ethiopia. MAY: senior lecturer of clinical pharmacy in Jimma University, Institute of Health, School of Pharmacy, Clinical Pharmacy Unit, Jimma, Ethiopia. Provides pharmaceutical care service in Jimma University Medical Center, Institute of Health, Jimma, Ethiopia. BTT: senior lecturer of clinical pharmacy in Jimma University, Institute of Health, School of Pharmacy, Clinical Pharmacy Unit, Jimma, Ethiopia. Provides pharmaceutical care service in Jimma University Medical Center, Institute of Health, Jimma, Ethiopia.

Funding

This project is funded by Jimma University’s research and innovation office. The funding body has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

Data generated and/or analyzed during this study are included in this article and its supplementary file [Additional file 1: ADE Dataset.csv]. In csv file all dates are mentioned in Ethiopian calendar. The dates are converted to Gregorian calendar in this article.

Declarations

Ethics approval and consent to participate

The study is ethically cleared by Jimma University, Institute of Health, Institutional review board (IRB No. IRB000/8920/20) and presented to WSUTRH. In addition, permission to conduct the study was gained from the respective heads of the department of internal medicine to conduct the study at the medical ward. After giving relevant information on the research purpose and process, written informed consent was requested from each participant, and we gave due emphasis on confidentiality. For participants with no formal education, informed consent was obtained from the legal guardian. The ADEs identified during the data collection were handled by the multidisciplinary team for resolution. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Hadiya Zone, West Badewacho Woreda Health Office, Addis Ababa, Ethiopia. 2 School of Pharmacy, Clinical Pharmacy Unit, Jimma University, Institute of Health, P.O.B. 378, Jimma, Ethiopia. 3 Jimma University Medical Center, Institute of Health, Jimma, Ethiopia.

References

1. WHO. Patient Safety. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/patient-safety. Cited 2022 Jan 10
2. Network PS. Medication errors and adverse drug events. 2019. Available from: https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events. Cited 2022 Jan 10
3. Donaldson MS, Corrigan JM, Kohn LT. To err is human: building a safer health system: National Academies Press; 2000.
4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA J Am Med Assoc. 1995;274(1):29–34.
5. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmahomed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. Plos One. 2009;4(2):1–7.
6. Gardina C, Cutoneo PM, Moccioaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (facilitation of reporting in hospital ward) study. Front Pharmacol. 2018;9(APR):1–12.
7. Pirmahomed M, James S, Meakin S, Green C, Scott AK, Wallay TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Br Med J. 2004;329(7456):15–9.
8. Benkirane RR, R-Abouqal R, Haimeur CC, El Kettani SSSEC, Azzouzi AA, M’daghri A, et al. Incidence of adverse drug events and medication errors in intensive care units: in Morocco: a prospective multicenter study. J Patient Saf. 2009;5(1):16–22.
9. Thumann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. 2001;24(13):961–8.
10. Yun IS, Koo MJ, Park EH, Kim SE, Lee JH, Park JW, et al. A comparison of active surveillance programs including a spontaneous reporting model for pharmacovigilance of adverse drug events in a hospital. Korean J Intern Med. 2012;27(4):443–50.
11. Field TS, Gurwitz JH, Harold LR, Rothschild JM, Debellis K, Seger AC, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Informatics Assoc. 2004;11(6):492–8.
12. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Intern Med. 2011;26(2):148–53.
13. Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Heal Care. 2013;25(6):648–55.
14. Kiguba R, Karamagi C, Bird SM. Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients. BMJ Open. 2017;7(7):1–11.
15. Sahlu T, Getachew M, Melaku T, Selenke T. Adverse drug events and contributing factors among hospitalized adult patients at Jimma medical center, Southwest Ethiopia: a prospective observational study. Curr Ther Res. Clin Exp 2020;93:100611.
16. Oscanao TJ, Lizarazo F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759–70.
17. Chan SL, Ang X, Sani LL, Ng HY, Winther MD, Liu JI, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharmacol. 2016;82(6):1636–46.
18. Jolivot PA, Hindlet P, Piccheau C, Fernandez C, Maury E, Guilet B, et al. Systematic review of adult admissions to ICUs related to adverse drug events. Crit Care. 2014;18(6):643.
19. Zied P, Haught C, Black KJL, Fitzpatrick EA, Ackroyd-Stolarz S, Murphy NG, et al. Medication-related emergency department visits and hospital admissions in pediatric patients: a qualitative systematic review. J Pediatr. 2013;163(2):477–83.
20. Nazer LH, Eljaber R, Rimawi D, Hawari FI. Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract. 2013;19(4):298–304.

Received: 21 January 2022 Accepted: 9 May 2022
Published online: 17 May 2022
21. Betteridge TM, Frampton CM, Jardine DL. Polypharmacy - we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J. 2012;42(2):208–11.

22. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7–8):1017–25.

23. Einanson TR, Gutierrez LM, Rudis M. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7–8):832–40.

24. Hallas J, Harvald B, Worm J, Beck-Nielsen J, Gram LF, Grodum E, et al. Drug related hospital admissions - results from an intervention program. Eur J Clin Pharmacol. 1993;45(3):199–203.

25. Mejia G, Saiz-Rodriguez M, Gómez de Olea B, Ochoa D, Abad-Santos F. Urgent hospital admissions caused by adverse drug reactions and medication errors—a population-based study in Spain. Front Pharmacol. 2020;11:734.

26. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. J Am Med Assoc. 1997;277(4):301–6.

27. Lee SM, Kim CM, Lim SJ, Suh DC. Impact of adverse drug events on hospital length of stay and hospitalization costs in hospitals for 2003-2009 in the United States. Value Heal. 2013;16(3):A202.

28. Fasipe OJ, Akhdidiene PE, Owhim OS. The observed effect of adverse drug reactions on the length of hospital stay among medical inpatients in a Nigerian University teaching hospital. Toxicol Res Appl. 2019;3:239784731985045.

29. Vargas E, Terleira A, Hernando F, Perez E, Cordón C, Moreno A, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694–8.

30. Vinet L, Zhedanov A. A "missing" family of classical orthogonal polynomials. J Phys A Math Theor. 2011;44(8):1689–99.

31. Partin B. Preventing medication errors: an iom report. Nurse Pract. 2006;31(12):8.

32. Department of Health. The report of the short life working group on reducing medication-related harm: Acute Care and Workforce/Acute Care and Quality/CGC Iaqp. 2018. p. 24.

33. Moyer E, Carminie E, Stefffox HT. Clinical review: medication errors in critical care. Crit Care. 2008;12(1):1–7.

34. Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J, et al. The Canadian adverse events study: the incidence of adverse events among hospital patients in Canada. CMAJ. 2004;170(11):1678–86.

35. Palanisamy S, Arulkumaran KSG, Rajasekaran A. A prospective study on adverse drug reactions in a tertiary care south Indian hospital. Indian J Pharm Pract. 2013;6(2):49–60.

36. De Boer M, Boeker EB, Ramsattan MA, Kiewiet JJS, Dijkgraaf MGW, Boemerste MA, et al. Adverse drug events in surgical patients: an observational multicentre study. Int J Clin Pharm. 2013;6(2):49–60.

37. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Northfield Il). 2016;16(5):481.

38. Angamto MT, Curtain CM, Chalmers L, Yilmaz D, Bereznicki L. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: a prospective cross-sectional study. Plos One. 2017;12(10):e0171995.

39. Griffin FA, Resar RK. IHI global trigger tool for measuring adverse events. Cambridge: Institute for Healthcare Improvement; 2009.

40. Charlton M. In: Cal M, editor. Charlson Comorbidity Index (CCI), vol. 2021, 2020.

41. Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Informatics Assoc. 1998;5(3):305–14.

42. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.

43. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–32.

44. Kumar PU, Adhikari P, Periera P. A prospective analysis of adverse drug reactions in a south Indian hospital. Online J Health Allied Sci. 2009;8(3):1–6.

45. Rydberg DM, Holm L, Engqvist L, Frykstedt J, Lindh JD, Stiller CO, et al. Adverse drug reactions in a tertiary care emergency medicine ward: prevalence, preventability and reporting. Plos One. 2016;11(9):1–14.

46. Hug BL, Witkowski DJ, Sox CM, Keohane CA, Seger DL, Yoon C, et al. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J Gen Intern Med. 2010;25(1):31–8.

47. Sarjib A, Sarvar MR, Sarfraz M, Ifthikar S. Causality and preventability of adverse drug events of antibiotics among inpatients having different lengths of hospital stay: a multicenter, cross-sectional study in Lahore, Pakistan. BMC Pharmacol Toxicol. 2018;19(1):1–14.

48. Sahwal HS, Upmanyu S. Incidence of adverse drug events among hospitalized patients in surgical wards: a hospital based study. Int Arch BioMed Clin Res. 2018;4(1):134–6.

49. Rozenfeld S, Giordani F, Coelho S. Adverse drug events in hospital; pilot study with trigger tool. Rev Saude Publica. 2013;47(6):1102–11.

50. Esthetie TC, Hailemeskel B, Mekonnen N, Paulos G, Mekonnen AB, Girma T. Adverse drug events in hospitalized children at Ethiopian University hospital: a prospective observational study. BMC Pediatr. 2015;15(1):1–8.

51. Chung-delgado K, Revilla-montag A, Guillen-bravo S, Velero–E. Silva-casio W, Sorla-montoya A, et al. Factors associated with anti-tuberculosis medication adverse Effects: a case-control study in Lima, Peru. Plos One. 2011;6(11):1–5.

52. Merid MW, Gezie LD, Kassa GM, Muluneh AG. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line antituberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infect Dis. 2019;28(6):19:1–12.

53. Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs Stand. 2016;30(50):53–63.

54. Nguyen TL, Leguenelina-Blache G, Kinowski JM, Roux-Marson C, Rougier M, Spence J, et al. Improving medication safety: development and impact of a multivariate model-based strategy to target high-risk patients. Plos One. 2017;12(2):e0171995.

55. Giordani F, Rozenfeld S, Martins M. Adverse drug events identified by triggers at a teaching hospital in Brazil, 2014. p. 1–8.

56. Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2019;6(27):e010831.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.